Abstract
Proinflammatory cytokines released from monocytes / macrophages, in particular tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, and IL-8 seem to play an important role in Inflammatory Bowel Disease (ulcerative colitis and Crohns disease). Endotoxins or lipopolysaccharides, derived from the outer membrane of Gram-negative bacteria interact with CD14 on surface membrane of macrophages, thus triggering a signal cascade, which leads to the production and release of proinflammatory cytokines, particularly TNF-α. Therefore, in IBD, lipopolysaccharides could play a pathogenic role. In this respect, plasma endotoxins have been demonstrated in a not negligible percentage of patients with ulcerative colitis and in their unaffected relatives. The presence of circulating endotoxins could be due, at least in part, to the impaired natural immunity in either patients with ulcerative colitis or in their first degree unaffected relatives. Lactoferrin is an iron-binding glycoprotein, which binds to the lipid A region of lipopolysaccharide with a high affinity and this interaction prevents the binding of lipopolysaccharide to CD14, thus inhibiting the release of proinflammatory cytokines. Therefore, based on the possible pathogenic role exerted by endotoxins in ulcerative colitis, lactoferrin may deserve attention as a possible therapeutical agent in experimental models of Inflammatory Bowel Disease.
Current Pharmaceutical Design
Title: Immune Abnormalities and Endotoxemia in Patients with Ulcerative Colitis and in Their First Degree Relatives: Attempts at Neutralizing Endotoxin- Mediated Effects
Volume: 9 Issue: 24
Author(s): L. Amati, L. Caradonna, G. Leandro, T. Magrone, M. Minenna, G. Faleo, N. M. Pellegrino, E. Jirillo and D. Caccavo
Affiliation:
Abstract: Proinflammatory cytokines released from monocytes / macrophages, in particular tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, and IL-8 seem to play an important role in Inflammatory Bowel Disease (ulcerative colitis and Crohns disease). Endotoxins or lipopolysaccharides, derived from the outer membrane of Gram-negative bacteria interact with CD14 on surface membrane of macrophages, thus triggering a signal cascade, which leads to the production and release of proinflammatory cytokines, particularly TNF-α. Therefore, in IBD, lipopolysaccharides could play a pathogenic role. In this respect, plasma endotoxins have been demonstrated in a not negligible percentage of patients with ulcerative colitis and in their unaffected relatives. The presence of circulating endotoxins could be due, at least in part, to the impaired natural immunity in either patients with ulcerative colitis or in their first degree unaffected relatives. Lactoferrin is an iron-binding glycoprotein, which binds to the lipid A region of lipopolysaccharide with a high affinity and this interaction prevents the binding of lipopolysaccharide to CD14, thus inhibiting the release of proinflammatory cytokines. Therefore, based on the possible pathogenic role exerted by endotoxins in ulcerative colitis, lactoferrin may deserve attention as a possible therapeutical agent in experimental models of Inflammatory Bowel Disease.
Export Options
About this article
Cite this article as:
Amati L., Caradonna L., Leandro G., Magrone T., Minenna M., Faleo G., Pellegrino M. N., Jirillo E. and Caccavo D., Immune Abnormalities and Endotoxemia in Patients with Ulcerative Colitis and in Their First Degree Relatives: Attempts at Neutralizing Endotoxin- Mediated Effects, Current Pharmaceutical Design 2003; 9 (24) . https://dx.doi.org/10.2174/1381612033454324
DOI https://dx.doi.org/10.2174/1381612033454324 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Manifestations in Inflammatory Bowel Disease
Current Cardiology Reviews Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs
Current Medicinal Chemistry Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety NLRP3: A Promising Therapeutic Target for Inflammatory Bowel Disease
Current Drug Targets Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Cytokines, Inflammation and Colon Cancer
Current Cancer Drug Targets Exploring the Phosphatidylcholine in Inflammatory Bowel Disease: Potential Mechanisms and Therapeutic Interventions
Current Pharmaceutical Design Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?
Inflammation & Allergy - Drug Targets (Discontinued) An Update on Herbal Products for the Management of Inflammatory Bowel Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Diagnosis of Inflammatory Bowel Disease by Abdominal Ultrasound and Color Doppler Techniques
Current Medical Imaging Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology Ulcerative Colitis: Pathogenesis
Current Drug Targets Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Current Concepts on the Genetics and Pharmacogenetics of Inflammatory Bowel Disease: Do they Help in Clinical Management?
Current Genomics Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Probiotics for Inflammatory Bowel Disease; A Deep Dive into their Impact on Disease Course and Associated Health Risks
Current Medicinal Chemistry